Identification and Validation of Afatinib Potential Drug Resistance Gene BIRC5 in Non-Small Cell Lung Cancer

INTRODUCTION: Resistance to second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), afatinib, is the most significant challenge in the clinical management of non-small cell lung cancer (NSCLC), and the underlying mechanisms remain unclear. METHODS: Genomic signatures...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Xiaoxi, Zhou, Renyu, Lu, Yuanzhi, Zhang, Ying, Chen, Qiang, Li, Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595596/
https://www.ncbi.nlm.nih.gov/pubmed/34804966
http://dx.doi.org/10.3389/fonc.2021.763035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595596/
https://www.ncbi.nlm.nih.gov/pubmed/34804966
http://dx.doi.org/10.3389/fonc.2021.763035

Ejemplares similares